Pegteograstim may be effective for reducing chemotherapy-induced neutropenia

the ONA take:

Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer undergoing myelosuppressive chemotherapy, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.

For the phase 2/3 study, researchers sought to evaluate the efficacy and safety of pegteograstim, a new formulation of pegylated granulocyte-colony-stimulating factor (G-CSF), compared with pegfilgrastim in preventing febrile neutropenia.

In the phase 3 portion, researchers enrolled 117 patients with breast cancer who were undergoing treatment with docetaxel plus doxorubicin or docetaxel plus doxorubicin and cyclophosphamide.

Patients were randomly assigned to receive pegteofilgrastim 6.0 mg subcutaneously on day 2 of chemotherapy or pegfilgrastim 6.0 mg subcutaneously.

Results showed that the efficacy of pegteograstim was noninferior to that of pegfilgrastim in the duration of grade 4 neutropenia during cycle 1 of chemotherapy.

Furthermore, the time to absolute neutrophil count recovery was significantly shorter with pegteograstim compared with pegfilgrastim.

In regard to safety, treatment-related adverse events did not differ significantly between the two treatment arms.

Genetic testing was associated with lower chemotherapy use in high-risk patients and greater use in
Pegteograstim is as effective as pegfilgrastim in reducing chemotherapy-induced neutropenia in patients with breast cancer.
Pegylated granulocyte-colony-stimulating factor (G-CSF) is frequently used to prevent febrile neutropenia (FN) in patients undergoing chemotherapy with a high risk of myelosuppression. This phase II/III study was conducted to determine the adequate dose of pegteograstim, a new formulation of pegylated G-CSF, and to evaluate the efficacy and safety of pegteograstim compared to pegfilgrastim.
READ FULL ARTICLE From Springer
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs